𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

✍ Scribed by Ninh M. La-Beck; Beth A. Zamboni; Alberto Gabizon; Hilary Schmeeda; Michael Amantea; Paola A. Gehrig; William C. Zamboni

Publisher
Springer
Year
2011
Tongue
English
Weight
348 KB
Volume
69
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Multicenter study of pegylated liposomal
Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma
✍ Uwe Wollina; Reinhard Dummer; Norbert H. Brockmeyer; Helga Konrad; J.-O. Busch; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 96 KB

## Abstract ## BACKGROUND In single center studies and case reports, it was shown that pegylated liposomal doxorubicin (PEG‐DOXO) was effective as second‐line therapy for patients with cutaneous T‐cell lymphoma (CTCL). The objective of this study was to evaluate the efficacy and toxicity of single

Phase I study of pegylated liposomal dox
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie